BIOMAT Database Logo BIOMAT Database Logo

[Phase II trial with cisplatin in ovarian malignancies]. 1982

T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
April 1999, Gynecologic oncology,
T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida
A phase I-II trial of cisplatin, hyperthermia and radiation in patients with locally advanced malignancies.
December 1989, International journal of radiation oncology, biology, physics,
T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida
Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.
February 2001, Cancer,
T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
January 2021, PloS one,
T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
May 2004, Clinical cancer research : an official journal of the American Association for Cancer Research,
T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida
A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin.
October 1990, American journal of clinical oncology,
T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida
A phase II trial of adjuvant cisplatin and doxorubicin in stage I epithelial ovarian cancer.
December 1991, Gynecologic oncology,
T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida
Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer.
January 1994, Journal of cancer research and clinical oncology,
T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida
A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
March 1991, Gynecologic oncology,
T Hosokawa, and H Ito, and T Tanaka, and K Ichinoe, and Y Yamada, and M Suzuki, and A Yajima, and T Mori, and H Takamizawa, and S Sekiya, and S Sakamoto, and T Kawana, and J T Chen, and M Takada, and H Takeuchi, and K Akiya, and S Hara, and Y Hara, and S Takeuchi, and K Kanazawa, and H Yoshizawa, and Y Tomoda, and M Ohta, and S Hattori, and Y Yagami, and K Mizuno, and K Koike, and Y Suzuoki, and R Totani, and T Miwa, and O Sugimoto, and A Fujimoto, and S Doi, and S Tojo, and M Iwasaki, and K Sekiba, and I Kohno, and H Okazaki, and S Ogawa, and M Seto, and Y Komoto, and I Taki, and N Tsukamoto, and T Iwasaka, and T Yamabe, and H Nakajima, and M Yoshida
[Early phase II trial of bestrabucil in hematological malignancies].
June 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!